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Abstract
Background: The Juniper Asthma Specific Quality of Life Questionnaire (AQLQ(S)) is a questionnaire that allows
measurement of disease specific quality of life. We wanted to examine correlations between the (AQLQ(S)) general
and different subscale scores and both psychiatric morbidity and levels of psychological distress in individuals with
occupational asthma (OA) and to determine if results in the emotional function subscale allow identification of
individuals with clinically significant psychological distress or current psychiatric disorders.
Methods: This was a cross-sectional study of individuals with OA who were assessed during a re-evaluation for
permanent disability, after they were no longer exposed to the sensitizing agent. Patients underwent a general
sociodemographic and medical history evaluation, a brief psychiatric interview (Primary Care Evaluation of Mental
Disorders, PRIME-MD) and completed a battery of questionnaires including the AQLQ(S), the St-Georges Respiratory
Questionnaire (SGRQ), and the Psychiatric Symptom Index (PSI).
Results: There was good internal consistency (Cronbach alpha = 0.936 for the AQLQ(S) total score) and construct
validity for the AQLQ(S) (Spearman rho = -0.693 for the SGRQ symptom score and rho = -0.650 for the asthma
severity score). There were medium to large correlations between the total score of the AQLQ(S) and the SGRQ
symptom score (r = -.693), and PSI total (r = -.619) and subscale scores (including depression, r = -.419; anxiety,
r = -.664; anger, r = -.367; cognitive disturbances, r = -.419). A cut-off of 5.1 on the AQLQ(S) emotional function
subscale (where 0 = high impairment and 7 = no impairment) had the best discriminative value to distinguish
individuals with or without clinically significant psychiatric distress according to the PSI, and a cut-off of 4.7 best
distinguished individuals with or without a current psychiatric disorder according to the PRIME-MD.
Conclusions: Impaired quality of life is associated with psychological distress and psychiatric disorders in
individuals with OA. Findings suggest that the AQLQ(S) questionnaire may be used to identify patients with
potentially clinically significant levels of psychological distress.
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Background
Asthma is a chronic inflammatory disorder of the airways.
Occupational asthma (OA) is asthma that is caused and
maintained by conditions attributable to the occupational
environment and not to stimuli encountered outside the
workplace [1]. The impact of a disease on a patient’s
health and well-being is individual. According to Paul
Jones, “Ap a t i e n t ’s health-related quality of life is the result
of a generic disturbance to health common to all patients
with the disease, modulated by factors that are internal
and unique to the individual.” [2]. Health-related quality of
life questionnaires should therefore contain items evaluat-
ing physical, psychological and social domains, and in gen-
eral, the item content of a questionnaire should be derived
from patients rather than health professionals [3].
There are a variety of different measures available to
determine asthma-related quality of life according to a
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s u r e si st h eA s t h m aQ u a l i t yo fL i f eQ u e s t i o n n a i r e
(AQLQ) developed in Canada by Juniper and co-work-
ers. This questionnaire is available in approximately 80
languages, and changes in AQLQ scores have been
shown to have strong correlations with changes in
asthma control and medication usage [5]. Juniper and
co-workers found moderate cross-sectional correlations
of the AQLQ subscales with the psychosocial function
domain of the Sickness Impact Profile and the emotion
subscale of the Rand General Health Survey [5]. The
standardized version of the AQLQ(S) has been shown to
h a v eam o d e r a t ec r o s s - s e c t i o n a lc o r r e l a t i o n( r=0 . 4 8 )
with the mental component summary measures of the
Short Form-36 questionnaire [5,6].
Previous research has demonstrated a link between
health-related quality of life and an increased risk of all-
cause mortality and healthcare use in individuals with
asthma [7,8]. The goal of asthma treatment is therefore
to gain control of symptoms, which relies upon various
self-management behaviors such as daily symptom self-
monitoring, adherence to medication, refraining from
smoking, as well as managing environmental asthma
triggers. Chronic negative mood states such as depres-
sive or anxiety disorders may interfere with motivation
to engage in these self-management behaviors, and have
been linked to worse asthma-related quality of life [9].
Having depression has also been shown to be associated
with medication non-adherence in patients suffering
from different medical conditions,[10] and anxiety disor-
ders have been shown to be related to increased use of
bronchodilators (reliever medication) and decreased use
of controller medication such as inhaled corticosteroids
among asthmatics [9,11]. Early diagnosis of chronic
negative mood states therefore offers the opportunity to
begin specific anti-anxiety or anti-depressive therapy
(i.e., psychotherapy or pharmacotherapy), and has the
potential to reverse these adverse disease outcomes.
The aim of this study was to assess the correlation
between asthma-specific quality of life and both levels of
psychological distress and psychiatric disorders assessed
by standardized tools, in patients with OA. Specifically,
this study examined the correlation between general and
different subscale scores on the AQLQ(S) on the one
hand and, on the other hand, levels of psychological dis-
tress and rates of psychiatric disorders, and the extent
to which the responses on the emotion subscale of the
AQLQ(S) allowed for the identification of individuals
with significant psychological distress or psychiatric dis-
orders (i.e., patients who met diagnostic criteria for
depressive and anxiety disorders according to the Diag-
nostic and Statistical Manual of Mental Disorders, 4
th
Edition, DSM-IV).
Methods
Study design, setting and participants
This was a cross-sectional study of patients who claimed
compensation for OA at the Workers’ Compensation
Agency of Quebec (Commission de la santé et sécurité du
travail du Québec; CSST) in the years 2004 to 2006.
Patients who were no longer exposed to the sensitizing
agents causing OA for two years or more were evaluated
by two of the four Quebec CSST medical committees in
Montreal (Montreal Chest Institute and Hôpital du Sacré-
Coeur) for a permanent disability indemnity. In Quebec, all
patients who claim compensation for OA undergo specific
inhalation testing to confirm a diagnosis of OA. All clai-
mants scheduled for evaluation by the committees were
asked to participate in this study on a voluntary basis.
Patients were assessed when the participants were re-evalu-
ated to determine compensation for permanent disability.
Patients were assured that the medical committee would
not be informed of participation, nor of the assessment
results. They were given compensation for their study par-
ticipation to cover expenses like loss of salary and transpor-
tation or parking fees. All study participants gave written,
informed consent for their participation. The research pro-
tocol was approved by the Research Ethical Committee of
Hôpital du Sacré-Coeur de Montreal.
Measures
All patients underwent standard spirometry and methacho-
line challenge testing. All patients completed a question-
naire on chest and upper airway symptoms, medication
use, home allergen exposure, and smoking status. Patients
also completed a questionnaire assessing whether they
were still exposed to the sensitizing agent, as well as a
questionnaire assessing socio-economic factors. In addi-
tion, participants completed the validated French versions
of the following questionnaires:
Asthma Quality of Life Questionnaire (AQLQ(S))
The standardized version of the AQLQ(S) includes 32
items and evaluates asthma quality of life across four
domains that may be negatively affected by asthma. The
domains include 1) asthma symptoms 2) activity limita-
tions 3) emotional function and 4) exposure to environ-
mental stimuli. Every question is scored from one (severe
impairment) to seven (no impairment), and the total score
is the mean of the four scores [6]. Information on psycho-
metric properties of this instrument have been published
[12].
St-Georges Respiratory Questionnaire (SGRQ)
For this study, patients completed the section on
respiratory symptoms from the SGRQ to assess the
patient’s perception of their recent respiratory problems.
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where individuals choose the appropriate answer on a 5-
point Likert scale. Each item in the questionnaire has an
empirically derived weight. The total score is representing
the sum of these items. The total score ranges from 0 to
100 and a higher score indicates a worse symptom-related
HRQoL [13]. Information on psychometric properties of
this instrument have been published [12].
Psychiatric Symptom Index (PSI)
The PSI is a 29-item questionnaire designed to assess the
presence and intensity of psychological distress levels in
the past two weeks [14]. Items are scored using a four-
point scale from 0 (never) to 3 (very often). Total and sub-
scale scores (depression, anxiety, anger and cognitive
disturbance) are calculated as a percentage of the total
possible score out of 100. Scores of > 20 are considered to
indicate clinically significant levels of psychological distress
[14]. Information on psychometric properties of this
instrument have been published [15].
Primary Care Evaluation of Mental Disorders (Prime-MD)
The PRIME-MD is a validated brief screening instrument
designed to detect some of the most common psychiatric
disorders seen in community and medical settings [16]. It
consists of a 27-item patient self-report section followed
by a structured clinical interview that is used to follow-up
patient responses. The PRIME-MD evaluates 5 groups of
mental disorders (mood, anxiety, somatoform, alcohol,
eating), and items are based on the diagnostic criteria
from the DSM [17]. It has demonstrated very good sen-
sitivity (83%) for any psychiatric diagnosis and excellent
specificity (88%) across diagnostic modules [16]. We admi-
nistered the mood (depressive) and anxiety disorder mod-
ules, given they are the most prevalent psychiatric
disorders seen in asthma patients. We then classified indi-
viduals in two groups: either as having a mood and/or
anxiety disorder (any psychiatric disorder)o rn o th a v i n g
either mood or anxiety disorder (no psychiatric disorder).
Information on psychometric properties of this instrument
have been published [18].
Spirometry and Methacholine Provocation Testing
All patients underwent standard spirometry according to
ATS guidelines [19], using the reference values derived by
Knudson [20]. Methacholine challenge testing was per-
formed according to a previously published protocol [21].
Normal responsiveness was set at a concentration of
methacholine causing a 20% fall (PC20) in FEV1 of greater
than 16 mg*mL
-1[22].
Compound Asthma Severity Score
OA severity was calculated according to the Quebec
Workers’ Compensation Board Scale for OA: 0% = low
severity, 100% = maximum severity [23]. This scale
assesses three factors in the same way as the one pro-
posed by the American Medical Association [24]: level
of bronchial caliber, degree of bronchial responsiveness,
and need for medication to control asthma [25].
Statistical analyses
Continuous data are reported as means ± standard devia-
tions or medians and 25 and 75 percentiles. Proportions
were compared by using Chi-Square or Fisher’s exact test
if the expected cell count was < 5. Continuous variables
were compared by using the Mann-Whitney U test. For all
data analyses, we used the statistical software package
SPSS V.19 (SPSS Inc., Chicago, USA). A p-value of < 0.05
was considered statistically significant.
Measures of reliability
Cronbach alpha’s were calculated to assess the internal
consistency of the AQLQ(S) total score and each subscale
score. Cronbach’s alpha is a numerical coefficient for
reliability. The coefficient value ranges from 0 to 1, and
the higher the score, the more reliable is the generated
scale [26].
Measures of validity
We calculated Spearman’s rho for correlation analyses
between two continuous variables, and we conducted
point-biserial correlations which allow measurement of
the correlation between a continuous variable (AQLQ(S)
or PSI total or subscale scores) and a dichotomous variable
(any psychiatric disorder or no psychiatric disorder accord-
ing Prime-MD) [27]. The correlation was considered small
for correlation coefficients between 0.1 and 0.3, medium
between 0.3 and 0.5 and high between 0.5 and 1.
Receiver operator characteristic (ROC) curve and Youden
Index (YI)
In order to determine the best cut-off level of the AQLQ
(S) emotion subscale score for the diagnosis of clinically
relevant anxiety and depressive symptoms according to
the PSI, and mood and/or anxiety disorders according to
t h eP R I M E - M D ,aR O Cc u r v ew a sp l o t t e d .T h eY Iw a s
calculated to capture the performance of the diagnostic
test and to obtain the cut-off in the AQLQ(S) emotion
subscale score. YI was calculated as follows: (Sensitivity
+Specificity)-1 [28].
Linear and logistic regression models
As data of the dependent variable (PSI anxiety and
depression subscale scores) were not normally distributed
we performed logarithmic transformation and then,
applied the second power to this data prior to performing
linear regression. The presence of a psychiatric disorder
(mood and/or anxiety) was assess by the PRIME-MD and
Miedinger et al. Health and Quality of Life Outcomes 2011, 9:76
http://www.hqlo.com/content/9/1/76
Page 3 of 10coded as a dichotomous variable (yes, no). We used the
presence of psychiatric disorder as dependent variable
and entered the questions of the AQLQ(S) emotions sub-
scale score as independent variables in the model. We
used the automatic stepwise procedure of the statistical
package with a probability of F ≤ 0.05 to enter and the
probability of F ≥ 0.10 to remove the co-variate.
Results
Patient characteristics
Seventy-three subjects were eligible to participate during
the study period. We were unable to contact five subjects
and eight subjects refused to participate, yielding a final
sample of 60 subjects and a participation rate of 82%.
Participants did not differ from non-participants with
respect to sex, age at diagnosis, atopy, smoking status,
lung function, hyper-reactivity to methacholine, propor-
tion of subjects with OA caused by low molecular weight
agents, and the number of years at the workplace with
symptoms (data not shown).
The mean age of participants was 47.2 ± 11.7 years,
75% (n = 45) of which were male. The median duration
of exposure to the causal agent was 10.5 years (Q1;Q3:
3.1;22.8 years). A total of 42% (n = 25) were current smo-
kers. Fifty-five percent (n = 33) of participants were
working at the time of re-evaluation, 20% (n = 12) were
retired, 20% (n = 12) were unemployed, and 5% (n = 3)
were currently on re-training for another job. Thirty-one
percent (n = 19) reported their overall health status as
being fair or poor.
Asthma-specific quality of life, levels of psychological
distress, and the frequency of psychiatric disorders
a s s e s s e da tt h er e - e v a l u a t i o na r es h o w ni nT a b l e1 .
Thirty five percent (n = 21) had one or more psychiatric
disorder, 19 of whom had a mood disorder, 9 of whom
had an anxiety disorder, and 2 of whom had both a
mood and anxiety disorder according to the PRIME-MD
evaluation.
Psychometric properties of the AQLQ(S)
The internal consistency for the AQLQ(S) in this sample
was high, with Cronbach alpha’s of 0.934 for the emotion,
0.951 for the symptom, 0.922 for the activity, and 0.819
for the environment subscale scores, and 0.936 for the
total score. The observed cross-sectional correlations
between the AQLQ(S) total and subscale scores with the
compound asthma severity score incorporating lung
function, bronchial hyperactivity, and current medication
support a discriminative validity of the AQLQ(S) and can
be seen in Table 2.
Table 1 Description of Quality of Life, Psychological Distress and Psychiatric Disorders
Frequency (n (%)) Score (median (Q1;Q3))
Juniper AQLQ(S)
Symptoms 4.5 (3.5;6.0)
Activity limitations 4.6 (3.3;5.7)
Emotional function 5.0 (3.6;6.6)
Exposure to environmental stimuli 4.8 (3.3;5.8)
Total 4.6 (3.6;5.9)
SGRQ Asthma Symptom Score (%) 45 (32;71)
Psychological distress (PSI score > 20)
Depression 32 (53) 23.0 (10.0;33.0)
Anxiety 36 (60) 24.0 (12.8;39.0)
Anger 30 (50) 19.0 (8.0;33.0)
Cognitive disturbance 31 (52) 24.5 (8.0;39.8)
Total 34 (57) 24.5 (10.8;37.8)
Prime-MD
Any psychiatric disorder 21 (35)
Any mood disorder 19 (32)
- Major depression 8 (13)
- Dysthymia 3 (5)
- Minor depression 11 (18)
Any anxiety disorder 9 (15)
- Panic disorder 1 (2)
- Generalized anxiety 1 (2)
- Other anxiety disorder 7 (8)
Legend: AQLQ(S) = Standardized version of the Juniper Asthma Quality of Life Questionnaire; SGRQ: St. George Respiratory Questionnaire; PSI = Psychiatric
Symptom Index, PRIME-MD = Primary Care Evaluation of Mental Disorders questionnaire
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We investigated the construct validity of the AQLQ(S)
and calculated correlation coefficients for the different
AQLQ(S) scores with the compound asthma severity
score according to the Quebec Workers’ Compensation
Board Scale for OA as well as the symptom score of the
SGRQ. All combinations of scores between the continu-
ous measures yielded significant medium to high corre-
lations (Table 2).
Correlation between AQLQ and measures of
psychological distress
We then calculated correlation coefficients for the different
AQLQ(S) scores with the PSI total and subscale scores. All
combinations of scores between the continuous measures
yielded significant medium to high correlations, which can
be seen in Table 2. The highest correlation was found
between the PSI anxiety subscale score and the AQLQ(S)
total score and most of the AQLQ(S) subscale scores.
Table 2 Correlation of the Asthma Quality of Life Questionnaire by Juniper with Psychiatric Symptom Index, the
PRIME-MD evaluation, the St.George Respiratory Questionnaire and the Asthma Severity Compound Score
AQLQ
Symptoms
AQLQ
Activity
limitations
AQLQ Emotional
functions
AQLQ Exposure
to environmental
stimuli
AQLQ Total
Score
Asthma Severity Compound Score -0.582* -0.611* -0.627* -0.561* -0.650*
SGRQ Symptom Score -.686* -.650* -.610* -.574* -.693*
PSI Anxiety -.623* -.648* -.609* -.616* -.664*
PSI Anger -.331* -.376* -.344* -.404* -.367*
PSI Depression -.558* -.611* -.507* -.639* -.605*
PSI Cognitive disturbance -.426* -.401* -.373* -.432* -.419*
PSI Total Score -.583* -.613* -.553* -.622* -.619*
PRIME-MD
Anxiety
0.254 0.163 0.261§ 0.213 0.236
PRIME-MD
Mood
0.352* 0.381* 0.334* 0.402* 0.393*
PRIME-MD
Psychiatric disorder
0.396* 0.361* 0.389* 0.427* 0.417*
Legend: * p < 0.01, § p < 0.05
Figure 1 Receiver operator curves for the AQLQ(S) emotion subscore in the diagnosis of clinically significant anxiety or depression.
ROC = Receiver operator characteristic curve. ROC for AQLQ(S) emotion subscore in the diagnosis of clinically significant anxiety (> 20 points in
the PSI anxiety subscore; AUC 0.740 (95%CI 0.608-0.872)). ROC for AQLQ(S) emotion subscore in the diagnosis of clinically significant depression
(> 20 points in the PSI depression subscore; AUC 0.843 (95%CI 0.741-0.945)).
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AQLQ(S) emotion subscale for the detection of clinically
significant levels of psychological distress according to the
anxiety and depression subscales of the PSI. The highest
Youden index of 0.53 was obtained when choosing less
than 5.1 points as the cut-off for the diagnosis of clinically
significant anxiety according to the PSI (Figure 1). Fifteen
individuals were misclassified: Ten individuals had AQLQ
(S) scores greater than 5.1 points but were classified as
having scores greater than 20 points on the PSI anxiety
subscale, whereas 5 individuals had scores than 5.1 points
on the AQLQ(S) emotion subscale but had scores less
t h a n2 0o nt h eP S Ia n x i e t ys u b s c a l e( F i g u r e2 ) .B yu s i n g
this cut-off sensitivity was 72%, specificity 79%, positive
predictive value 84% and negative predictive value 66% for
the diagnosis of clinically significant anxiety symptoms
according to the PSI. The highest Youden index of 0.63
was obtained when choosing less than 5.1 points as the
cut-off for the diagnosis of clinically significant depressive
symptoms (Figure 1). Eleven individuals were misclassified:
Six individuals had AQLQ(S) scores greater than 5.1
points but were classified as having scores greater than
20 points on the PSI depression subscale, whereas 5 indivi-
duals had scores less than 5.1 points in the AQLQ(S) emo-
tion subscale but had scores less than 20 points on the PSI
depression subscale (Figure 2). By using this cut-off sensi-
tivity was 81%, specificity 82%, positive predictive value
84% and negative predictive value 79% for the diagnosis of
clinically significant depressive symptoms according to the
PSI.
When performing linear regression on the PSI anxiety
subscale score as the dependent variable, the questions
“feeling concerned about having asthma” and “feeling
afraid of getting out of breath” were significantly asso-
ciated (ß = -0.222 S.E. 0.106, p = 0.041 and ß = -0.220,
S.E. 0.104, R2 = 0.040). The question “feeling afraid of
getting out of breath” was associated with the PSI depres-
sion subscale score and the PSI total score (ß = -0.332
S.E. 0.084, p < 0.001, R2 = 0.231 and ß = -0.392, S.E.
0.078, R2 = 0.313, respectively).
Correlation between AQLQ and measures of psychiatric
disorders
We calculated point bi-serial correlations with indivi-
duals having an anxiety disorder, mood disorder, or any
psychiatric disorder according to the PRIME-MD. Having
any mood or any psychiatric disorder showed significant
correlations in the medium range for all the AQLQ(S)
subscale scores and the AQLQ(S) total score. There was
a small point-biserial correlation between having anxiety
disorder and the AQLQ(S) emotional function subscale
score, but not with the AQLQ(S) total score.
For classifying patients with any psychiatric disorder
according to the PRIME-MD, a cut-off of less than 4.7
points in the AQLQ(S) emotion subscale misclassified
17/60 individuals: Six individuals had AQLQ(S) scores
of greater or equal 4.7 points but were classified as hav-
ing at least one psychiatric disorder, whereas 11 indivi-
duals had scores less than 4.7 points but were classified
as not having a psychiatric disorder according the
PRIME-MD (sensitivity 71%, specificity 72%, positive
predictive value 58% and negative predictive value 82%,
area under the curve 0.736 (95% CI 0.609-0.863; data
not illustrated)). When classifying patients with any psy-
chiatric disorder according the PRIME-MD, 4 out of 21
individuals had scores of ≤ 20 points on the PSI anxiety
Figure 2 Scatterplots showing the correlation of the AQLQ(S) emotion with the PSI anxiety subscale and the correlation of the AQLQ
(S) emotion with the PSI depression subscale. PSI = Psychiatric symptom index; AQLQ(S) = Asthma Quality of Life Questionnaire; FP = false-
positive; FN = false-negative.
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tion subscale. Five out of 21 individuals with a psychia-
tric disorder had scores of ≤ 20 points on the PSI
depression subscale and/or had AQLQ(S) scores of ≥
5.1 on the emotion subscale (Figures 2a and 2b).
After conducting stepwise logistic regression with any
anxiety disorder according PRIME-MD as dependent
variable, the question “feeling concerned about the need
to use medication” was the only one with a marginal
association (ß = 0.346, S.E. 0.178, p = 0.052, Cox&Snell
R2: 0.062). When any mood disorder and any psychiatric
disorder were used as dependent variables, the question
“feeling afraid of getting out of breath” showed significant
association with both (any mood disorder = ß = 0.456,
S.E. 0.165, p = 0.006, Cox&Snell R2: 0.137; any psychia-
tric disorder = ß = 0.508, S.E. 0.169, p = 0.003, Cox&Snell
R2: 0.166).
Discussion
We found high correlations between impaired asthma-
specific quality of life and standard measures of psycho-
logical distress, and moderate correlations between
impaired asthma-specific quality of life and psychiatric
morbidity (i.e., mood and anxiety disorders) in indivi-
duals with OA. A cut-off value of < 5.1 on the AQLQ
(S)’s emotion subscale could reliably identify individuals
with clinically significant levels of depressive and/or
anxiety symptoms who need further evaluation by an
validated psychiatric interview.
There is limited evidence about the association of psy-
chological stress and asthma morbidity in individuals with
OA [29]. When considering the available evidence about
the impact of this stress on individuals with non-occupa-
tional asthma, we can imagine that an additional psycholo-
gical burden is associated with OA. This is in accordance
with past findings where subjects with OA had slightly but
significantly higher impairment in asthma-specific quality
of life than those with non-occupational asthma, even
when controlling for asthma severity [30]. In a study of
asthmatics affiliated with a health maintenance organiza-
tion in the USA, patients with work exacerbated of asthma
had lower quality of life measured according to the mood
disturbance, social disruptions, and health concerns sub-
scales of the Mark’s Asthma Quality of Life questionnaire,
compared to those individuals with no work exacerbated
asthma [31].
Various and probably many unknown factors contri-
bute to impairment of quality of life in individuals with
asthma. Malo and co-workers have reported a weak but
significant correlation between the original AQLQ with
FEV1, bronchial responsiveness, and asthma severity in a
more extensive sample of individuals with occupational
and non-occupational asthma [30]. The AQLQ(S) used
in our study and the original AQLQ questionnaires
distinguish themselves on one point: in the AQLQ(S)’s
five generic activities (strenuous exercise, moderate exer-
cise, work-related activities, social activities, and sleep)
replaced specific activities that could be chosen by the
patient in the original questionnaire [6]. We could repro-
duce these findings and could find a larger correlation of
the AQLQ(S) subscales and total score with the objective
asthma severity score. We also found a large correlation
between the symptom domain of a widely used quality of
life questionnaire in chronic obstructive lung disease -
the St. George Respiratory Questionnaire, which provides
support for quality of life being related to factors other
than objective markers of disease severity.
It is currently unknown how treatment of psychological
distress or psychiatric morbidity (either using psy-
chotherapy or pharmacotherapy) might affect asthma
and psychosocial outcomes in individuals with OA. Dis-
ease management programs for major depressive disor-
ders have been shown to be beneficial in reducing the
severity of the depression, maintaining employment,
increasing short term adherence to medication and
improving the individuals quality of life while being cost-
effective [32]. It a recent systematic review, Lerner and
Henke have shown that individuals with depression have
higher unemployment rates, more absenteeism and lower
at-work performance than individuals without depression
[33]. When on medical leave, individuals with poor men-
tal health are at risk for prolonged work absence [34].
Co-morbid psychiatric disorders are one of the reasons
for the adverse socioeconomic outcomes in regards of
unemployment and income loss. As these disorders can
influence the individual’s adherence to medication, life-
style behaviors such as smoking and managing environ-
mental asthma triggers, it could at least partially explain
the persistent symptomatology and bronchial hyperre-
sponsiveness in many individuals with OA seen even
years after termination of the exposure to a sensitizing
agent [35,36].
We found medium to large correlations between the
individual AQLQ(S) and the PSI. In point-biserial corre-
lations between AQLQ(S) and PRIME-MD outcomes
such as having psychiatric disorder the correlations were
in the range small to medium. In a population sample in
Australia, major depression according to the PRIME-MD
was associated with dyspnoea, wakening at night and
morning symptoms in asthmatics and these symptoms
were shown to have the greatest impact on decrease in
quality of life scores in the SF-36 [37]. When using the
Hospital Anxiety and Depression (HAD) scale, Riming-
ton and co-workers found moderate correlation of the
HAD depression subscale and a somewhat lower correla-
tion of the HAD anxiety subscale with the AQLQ symp-
toms subscore in a sample of asthmatic patients
attending GP offices in the UK [38]. In that study, hardly
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on the one hand and lung function expressed as forced
expiratory volume in one second (FEV1) or peak flow on
the other hand could be demonstrated [38]. In contrast,
Hommel and co-workers reported anxiety and depression
to influence asthma specific quality of life measured with
the Living with Asthma Questionnaire (LWAQ). When
performing regression analysis, they demonstrated that
anxiety had an independent main effect on LWAQ when
the model was controlled for depression [39]. The impact
of concomitant depression and anxiety seems to be even
more deleterious for health related quality in life in indi-
viduals with chronic obstructive pulmonary disease [40].
The AQLQ(S) has been used in a large variety of clinical
therapeutic trials and many cross sectional studies on
patients with OA. Measuring quality of life with the
AQLQ(S) allows to determine the impact of asthma on
respiratory symptoms, emotional function, activity limita-
tion as well as environmental stimuli. These factors are
important to acknowledge in clinical practice when asses-
sing a patient with asthma. In our sample of individuals
with OA who have been removed from exposure to the
sensitizing agent, using a cut-off point of 5.1 in the emo-
tional function subscale most reliably distinguishes indivi-
duals with significant psychological distress, whereas a
cut-off of 4.7 can be used to identify individuals who are
at risk of relevant psychiatric disorder according to the
PRIME-MD evaluation. It is not the intention of the
authors to suggest that the evaluation of patients with the
AQLQ(S) emotional subscale can replace a structured
diagnostic interview by a psychiatrist - which is considered
to be the gold standard - for the diagnosis of psychiatric
diseases. Questionnaires such as the Hospital Anxiety and
Depression Scale (HADS) have been shown to have a sen-
sitivity of 66-78% and specificity of 83-97% for the diagno-
sis of either depression or anxiety disorders in a general
practice setting [41]. Therefore even administration of
tools specifically designed to screen for psychiatric disor-
ders would not allow making an accurate diagnosis and
starting treatment without performing a structured psy-
chiatric interview. The advantage of using the AQLQ(S)
questionnaire is that it is widely available and regularly
used in clinical practice and trials. It can therefore be used
as a screening test. Considering the results of the emo-
tional subscale will not only allow to measure the impact
of asthma on quality of life but also to identify some indi-
viduals in whom a more extensive investigation such as a
structured psychiatric interview is warranted. The diagnos-
tic performance of the test using a cut-off of < 5.1 in the
emotional subscale score of the AQLQ(S) is modest for
identification of clinically important psychological distress
according to the PSI. But the performance is less for the
diagnosis of current psychiatric disorders according to the
PRIME-MD which relies on the diagnostic criteria for
depressive and anxiety disorders according to the Diagnos-
tic and Statistical Manual of Mental Disorders, 4
th Edition,
DSM-IV. In fact the positive predictive value for the diag-
n o s i so fc u r r e n tp s y c h i a t r i cd i s e a s eb yu s i n gac u t - o f fo f
4.7 is close to the predictive value of flipping a coin and
would even be lower when this test would be performed
in a population with a lower prevalence of psychiatric dis-
orders. There is very limited data suggesting that anxiety
and depression are more common in workers in whom
the asthma is related to the workplace [42]. In our study
all individuals were compensated for OA and one could
expect that the prevalence of mood and anxiety disorders
is more prevalent in this population than in most other
populations of asthmatics. However there is currently no
data available to conclude that the prevalence of psychia-
tric disorders is lower in individuals with uncompensated
OA or in individuals with work-exacerbated asthma.
Further studies are needed to compare the correlation of
psychiatric disorders and psychological distress with
asthma specific quality of life measures, such as the
AQLQ(S), in individuals with OA, work-exacerbated
asthma and asthma that is unrelated to the workplace [41].
The AQLQ(S) emotional function subscale respon-
dents report on different aspects that have been grouped
in this domain by the developers of this questionnaire in
which the items relate to three broad dimensions (con-
cerns, anger and anxiety). When considering individual
questions of this domain, the one about feeling afraid of
getting out of breath was significantly associated with the
PSI depression subdomain and PRIME-MD mood disor-
der whereas the questions about feeling concern about
having asthma and about the need to use medication
were significantly associated with PSI anxiety levels and
PRIME-MD anxiety disorders respectively. Since our ana-
lysis was descriptive, we do not suggest to reduce items
that have not shown significant correlation with psycho-
logic distress or psychiatric disorders from the emotions
subdomain of the AQLQ(S) questionnaire.
Whereas the PSI is a continuous measure that provides
information about the number and severity of psycholo-
gical symptoms, PRIME-MD diagnoses are categorical:
individuals are classified as having a particular disorder
or not based on having fulfilled a defined number of
diagnostic criteria. Therefore, the severity of psychiatric
d i s o r d e r sa sm e a s u r e db yt h eP R I M E - M Dc a n n o tb e
quantified [43]. Clinically, anxiety and depressive symp-
toms (and disorders) overlap significantly, so it can some-
times be difficult to determine if these disorders are
separate entities or different manifestations of the same
disorder [39]. Due to the limited number of individuals
with OA included in our study, we were not able to
examine associations between AQLQ(S) scores and
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der, generalized anxiety disorder). To demonstrate these
associations, studies with larger samples of individuals
with OA are needed. Further our sample consisted of
manly male workers with OA and therefore one must be
cautious when extrapolating our findings to a population
of female workers as the prevalence of the different
forms of psychiatric disorders might be different [9].
Our study does not allow us to determine the relation of
causation. We did not have information available about
psychological distress or any psychiatric disorder prior to
the development of OA or at the time the diagnosis of OA
was made. Furthermore, we did not gather information
about concurrent or past behavioural or medical therapy
for psychiatric disorders in each individual. To our knowl-
edge, the prevalence of psychiatric disorders at the time of
diagnosis of OA and its devolution after removal from the
causing agent or workplace is currently unknown and thus
other studies are needed to investigate these factors in
prospective investigations. It is unclear how interventions
specifically targeted to decrease psychological distress or
psychiatric disorders change the natural course of both
conditions OA and concurrent mental disorders.
An important strength of the present study is that
extensive objective assessments including spirometry,
measurement of nonspecific bronchial hyperreactivity,
and specific inhalation testing were performed in all
individuals, the latter of which is considered the refer-
ence standard for a diagnosis of OA [44,45].
Conclusions
Our study suggests that it is important to consider conco-
mitant psychological distress and psychiatric morbidity in
individuals with OA, even when their exposure to the
causing allergen has ended. By performing disease-specific
quality of life assessment with the AQLQ(S), individuals
with significant psychological distress or psychiatric disor-
der could be identified and more elaborative and conclu-
sive investigations and if necessary treatment be offered.
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